Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Drug-induced adaptation along a resistance continuum in cancer cells

View ORCID ProfileGustavo S. França, View ORCID ProfileMaayan Baron, View ORCID ProfileMaayan Pour, Benjamin R. King, Anjali Rao, View ORCID ProfileSelim Misirlioglu, View ORCID ProfileDalia Barkley, View ORCID ProfileIgor Dolgalev, View ORCID ProfileKwan Ho-Tang, Gal Avital, Felicia Kuperwaser, Ayushi Patel, View ORCID ProfileDouglas A. Levine, View ORCID ProfileTimothee Lionnet, View ORCID ProfileItai Yanai
doi: https://doi.org/10.1101/2022.06.21.496830
Gustavo S. França
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gustavo S. França
Maayan Baron
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maayan Baron
Maayan Pour
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maayan Pour
Benjamin R. King
2Institute for Systems Genetics, NYU Grossman School of Medicine, New York, NY USA
3Bristol-Myers Squibb Company, Lawrenceville, New Jersey, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anjali Rao
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Selim Misirlioglu
4Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Selim Misirlioglu
Dalia Barkley
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dalia Barkley
Igor Dolgalev
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
5Applied Bioinformatics Laboratories, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Igor Dolgalev
Kwan Ho-Tang
4Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY
6Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, US
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kwan Ho-Tang
Gal Avital
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felicia Kuperwaser
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayushi Patel
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas A. Levine
4Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY
7Merck & Co., Inc., Rahway, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Douglas A. Levine
Timothee Lionnet
2Institute for Systems Genetics, NYU Grossman School of Medicine, New York, NY USA
8Department of Cell Biology, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timothee Lionnet
Itai Yanai
1Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY USA
9Department of Biochemistry & Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Itai Yanai
  • For correspondence: itai.yanai@nyulangone.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Advancements in rational drug design over the past decades have consistently produced new cancer therapies, but such treatments are inevitably countered through an adaptive process that fosters therapy resistance. Malignant cells achieve drug resistance through intrinsic and acquired mechanisms, rooted in genetic and non-genetic determinants. In particular, recent work has highlighted the role of intrinsic cellular heterogeneity in the emergence of transient drug-tolerant persister cells that survive drug treatment, as well as non-genetically driven cell plasticity toward stable resistance. However, these models do not account for the role of dose and treatment duration as extrinsic forces in eliciting cancer cell adaptation. Here, we show that these two components together drive the resistance of ovarian cancer cells to targeted therapy along a trajectory of cellular adaptation, that we denote the ‘resistance continuum’. We report that gradual dose exposure and prolonged treatment promote a continuous increase in fitness, and show that this process is mediated by evolving transcriptional, epigenetic and genetic changes that promote multiple cell state transitions. The resistance continuum is underpinned by the assembly of gene expression programs and epigenetically reinforced stress response regulation. Using both in vivo and in vitro models, we found that this process involves widespread reprogramming of cell survival pathways, including interferon response, lineage reprogramming, metabolic rewiring and oxidative stress regulation. Together, the resistance continuum reveals the dynamic nature of cellular adaptation, and carries implications for cancer therapies, as initial exposure to lower doses primes cells over time for increased resistance to higher doses. Beyond cancer, such continuous adaptation exposes a basic aspect of cellular plasticity, which may also be deployed in other biological systems such as development, immune response and host-pathogen interactions.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 25, 2022.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Drug-induced adaptation along a resistance continuum in cancer cells
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Drug-induced adaptation along a resistance continuum in cancer cells
Gustavo S. França, Maayan Baron, Maayan Pour, Benjamin R. King, Anjali Rao, Selim Misirlioglu, Dalia Barkley, Igor Dolgalev, Kwan Ho-Tang, Gal Avital, Felicia Kuperwaser, Ayushi Patel, Douglas A. Levine, Timothee Lionnet, Itai Yanai
bioRxiv 2022.06.21.496830; doi: https://doi.org/10.1101/2022.06.21.496830
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Drug-induced adaptation along a resistance continuum in cancer cells
Gustavo S. França, Maayan Baron, Maayan Pour, Benjamin R. King, Anjali Rao, Selim Misirlioglu, Dalia Barkley, Igor Dolgalev, Kwan Ho-Tang, Gal Avital, Felicia Kuperwaser, Ayushi Patel, Douglas A. Levine, Timothee Lionnet, Itai Yanai
bioRxiv 2022.06.21.496830; doi: https://doi.org/10.1101/2022.06.21.496830

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cancer Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4383)
  • Biochemistry (9601)
  • Bioengineering (7097)
  • Bioinformatics (24868)
  • Biophysics (12621)
  • Cancer Biology (9959)
  • Cell Biology (14358)
  • Clinical Trials (138)
  • Developmental Biology (7954)
  • Ecology (12110)
  • Epidemiology (2067)
  • Evolutionary Biology (15989)
  • Genetics (10929)
  • Genomics (14745)
  • Immunology (9871)
  • Microbiology (23680)
  • Molecular Biology (9486)
  • Neuroscience (50884)
  • Paleontology (369)
  • Pathology (1540)
  • Pharmacology and Toxicology (2683)
  • Physiology (4019)
  • Plant Biology (8657)
  • Scientific Communication and Education (1510)
  • Synthetic Biology (2397)
  • Systems Biology (6439)
  • Zoology (1346)